Abstract
The real-time quaking-induced conversion (RT-QuIC) assay has been developed and used as an in vitro diagnostic tool for Parkinson's disease (PD). In this study, we established α-Syn RT-QuIC using recombinant human α-Syn as the substrate. All 5 brain homogenates of neuropathological PD cases and 13 skin homogenates of clinical PD cases showed positive results, whereas all the samples of negative controls remain negative. Meantime, randomly selected 6 skin samples of PD cases and 6 skin samples of sCJD cases showed negative in opposite prion RT-QuIC and α-Syn RT-QuIC. Our α-Syn RT-QuIC showed dose-dependent manner between the lag times and peak ThT fluorescent values. Additionally, the detecting limitation was about 10<sup>-7</sup> dilution for brain tissues and 10<sup>-6</sup> for skins. Those data indicate a reliable specificity and good sensitivity of the established α-Syn RT-QuIC in identifying and amplifying the misfolded α-Syn in brain and skin tissues of patients with PD.
Introduction
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder classified as a "synucleinopathy," defined by the pathological accumulation of misfolded α-synuclein (α-Syn) proteins. Currently, a definitive diagnosis of PD requires post-mortem neuropathological examination. Clinical diagnosis during a patient's life relies on motor symptoms, which often overlap with other conditions, leading to potential misdiagnosis. While biomarkers in cerebrospinal fluid (CSF) have been explored, results are frequently inconsistent. There is an urgent need for a sensitive, specific, and minimally invasive diagnostic tool. This study, published in Frontiers in Aging Neuroscience, evaluates the efficacy of the α-Syn Real-Time Quaking-Induced Conversion (RT-QuIC) assay in detecting misfolded α-Syn in both brain and skin tissues of Chinese PD patients.
Methodology
RT-QuIC functions as a "molecular photocopier" for proteins, similar to how PCR amplifies DNA. The process involves:
- Seeding: A small amount of patient tissue (brain or skin homogenate) is introduced into the reaction.
- Substrate Interaction: Recombinant human α-Syn is provided as the substrate.
- Quaking: The mixture undergoes intermittent automated shaking to facilitate interaction.
- Conversion: If misfolded α-Syn (the "seed") is present, it triggers the normal recombinant substrate to misfold and aggregate into amyloid fibrils.
- Detection: Thioflavin T (ThT), a fluorescent dye, binds to these aggregates, allowing real-time monitoring of protein growth.
The study utilized 5 neuropathologically confirmed PD brain samples and 13 clinically diagnosed PD skin samples, alongside various controls including healthy individuals and patients with prion diseases like sporadic Creutzfeldt–Jakob disease (sCJD).
Key Results
The established α-Syn RT-QuIC assay demonstrated 100% sensitivity and specificity in this cohort. All 5 PD brain samples and all 13 PD skin samples tested positive, while all negative controls remained negative. The assay exhibited remarkable sensitivity, with detection limits reaching a $10^{-7}$ dilution for brain tissue and $10^{-6}$ for skin.
As shown in Figure 4, the assay typically follows a dose-dependent pattern: higher concentrations of the misfolded "seed" result in shorter lag times (the period before fluorescence rises) and higher peak ThT fluorescence. This relationship confirms the assay's ability to quantitatively reflect the presence of pathological α-Syn.
Discussion and Clinical Implications
A major finding of this study is that pathological α-Syn in the skin is "seed-competent," meaning it can trigger the same misfolding cascade as brain-derived protein. This validates skin biopsies—specifically from the retroauricular (scalp) area—as a viable, less invasive diagnostic window for PD. Furthermore, the assay showed high specificity; PD samples did not trigger prion-specific RT-QuIC, and sCJD samples did not trigger the α-Syn assay, distinguishing PD from other protein-misfolding disorders.
However, the researchers noted that in some instances, such as "PD Case 1" (Figure 6), higher tissue concentrations (e.g., $10^{-2}$) actually showed longer lag times than more dilute samples (e.g., $10^{-4}$). This suggests the presence of endogenous inhibitors in concentrated tissue. Consequently, the authors recommend testing multiple dilutions ($10^{-4}$ and $10^{-5}$) in clinical practice to ensure accuracy.
Conclusion
The α-Syn RT-QuIC assay is a robust tool for identifying misfolded α-synuclein in Chinese PD patients. While limited by a small sample size, the study provides a strong foundation for using skin biopsies as a reliable in vivo biomarker for Parkinson’s Disease. Future research with larger cohorts and varying biopsy sites will be essential to standardize this technique for widespread clinical use.
Summary updated